Alpha 2.0
Login Register
» Authors » Renee Holt

Renee Holt

Explore the profile of Renee Holt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 67
Followers 0
Related Specialties
Allergy & Immunology
Infectious Diseases
Top 10 Co-Authors
Jorge Flores
Francesco Berlanda Scorza
Yuxiao Tang
Suvaporn Anugulruengkitt
Souad Mansouri
Vu Minh Huong
Keswadee Lapphra
Librada Fortuna
Bruce L Innis
Niranjan Bhat
Published In
Vaccine
Hum Vaccin Immunother
Sex Transm Dis
Ther Adv Vaccines Immunother
Clin Trials
Affiliations
Soon will be listed here.
Recent Articles
1.
Development, implementation, and evaluation of an innovative clinical trial operations training program for Africa (ClinOps)
Ejigu D, Fekadu A, Whitty J, Manyazewal T, Nebeta P, Conradie A, et al.
BMC Med Educ . 2025 Jan; 25(1):119. PMID: 39856664
Background: Africa's involvement in clinical trials remains very low. Although the crucial role of training initiatives in building clinical trial capacity in Africa has been documented, current efforts fall short...
2.
Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines
Chokephaibulkit K, Puthanakit T, Chaithongwongwatthana S, Bhat N, Tang Y, Anugulruengkitt S, et al.
Vaccine . 2023 Dec; 42(2):383-395. PMID: 38061956
Introduction: Recombinant acellular pertussis (ap) vaccines containing genetically inactivated pertussis toxin (PT) and filamentous hemagglutinin (FHA) with or without tetanus (TT) and diphtheria (DT) vaccines (Td) were found safe and...
3.
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women
Puthanakit T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, Tang Y, Anugulruengkitt S, et al.
Vaccine . 2023 Jun; 41(31):4541-4553. PMID: 37330371
Introduction: Despite a decrease in infections caused by Bordetella pertussis due to COVID-19 pandemic, booster vaccination of pregnant women is still recommended to protect newborns. Highly immunogenic vaccines containing genetically...
4.
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age
Chokephaibulkit K, Puthanakit T, Bhat N, Mansouri S, Tang Y, Lapphra K, et al.
Vaccine . 2021 Nov; 40(15):2352-2361. PMID: 34789403
Background: A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis toxin (PT) was conducted in women of childbearing age in...
5.
Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults
Stevanovic G, Obradovic A, Ristic S, Petrovic D, Milenkovic B, Mitrovic D, et al.
Ther Adv Vaccines Immunother . 2020 Jun; 8:2515135520925336. PMID: 32518891
This study was a phase III, multicenter, double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a seasonal trivalent split, inactivated influenza vaccine (TIV) in healthy Serbian adults...
6.
A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1)
Duong T, Thiem V, Anh D, Cuong N, Thang T, Huong V, et al.
Vaccine . 2019 Dec; 38(6):1541-1550. PMID: 31812464
Background: A global shortfall of vaccines for avian influenza A(H5N1) would occur, especially in low- and-middle income countries, if a pandemic were to occur. To address this issue, development of...
7.
A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam
Lan P, Trong Toan N, Thang H, Thang T, Van Be L, Thai D, et al.
Hum Vaccin Immunother . 2019 May; 15(12):2933-2939. PMID: 31070986
: Under the WHO's Global Action Plan for influenza vaccines, we conducted a phase 2-3 study of IVACFLU-S, a trivalent, seasonal inactivated influenza vaccine candidate.: In the phase 2 portion...
8.
Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults
Stevanovic G, Lavadinovic L, Vignjevic S, Holt R, Ilic K, Scorza F, et al.
Hum Vaccin Immunother . 2017 Dec; 14(3):579-586. PMID: 29239682
This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The vaccine...
9.
Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam
Phan T, Ho V, Vu M, Nguyen T, Duong H, Holt R, et al.
Vaccine . 2016 Sep; 34(45):5449-5456. PMID: 27591953
We tested an inactivated egg-grown whole virus influenza A/H5N1 vaccine candidate developed by the Institute of Vaccines and Medical Biologicals (IVAC), a state-run vaccine manufacturer in Vietnam, in a Phase...
10.
Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults
Anh D, Thiem V, Anh N, Huong V, Nga N, Thang T, et al.
Vaccine . 2016 Aug; 34(45):5457-5462. PMID: 27567493
Background: Under the auspices of the World Health Organization (WHO) Global Action Plan, PATH supported evaluation of a trivalent, seasonal inactivated influenza vaccine candidate produced by the Institute of Vaccines...